The groups had similar median ages at presentation (69 vs 70 yrs, p¼0.35). Median maximum tumor diameter (MTD) at presentation was 20.3 mm (IQR 15-27 mm) vs. 54.3 mm (IQR 43-64 mm) (p<0.0001). Median LGR was faster in the LRM group (16.5 vs 22.8 mm/yr, p¼0.48) and median time to delayed intervention (DI) was less in the LRM group (30.6 vs 25.4 mo, p¼0.13) but neither difference was statistically significant. Rates of DI at 5 years (Figure 1) (37.1% [95% CI 32-42.9%] vs. 35.8% [95% CI 23.8-51.5%], p¼0.75) and OS at 5 years (Figure 2) (90.4% [95% CI 86.8-93.1%] vs 87.3% [95% CI 76-93.6%], p¼0.27) were not significantly different between the SRM and LRM groups, respectively. Five patients (1.1%) in the SRM group and zero patients in the LRM group died from renal cell carcinoma (RCC) (p¼0.61). CONCLUSIONS: At 5-years, AS AE DI appears safe in well selected patients with localized renal masses !4 cm. Metastasis and death from RCC were rare events and freedom from DI and OS were similar between LRM and SRM groups.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.